About Minerva Surgical
Minerva Surgical is a publicly listed company based in Redwood City (United States) founded in 2008. Minerva Surgical is focused on uterine health solutions. It operates on a Direct-to-Consumer (D2C) and Professional Services model. Minerva Surgical has raised $135.1 million across 16 funding rounds from investors including Accelmed and NEA. The company has 155 employees. Its chief executive, as recorded, is David Clapper. Minerva Surgical offers products and services including Minerva EAS, Symphion, Genesys HTA, Resectr, and HERizon. Its focus areas include Medical Devices and Gynecological Devices. Its legal entity is Minerva Surgical, Inc. Its competitors include Gynesonics, Channel Medsystems and LUMINELLE; 2 of its 3 listed competitors have raised funding.
Company details
Minerva Surgical, Inc. is dedicated to advancing womens uterine health through innovative medical devices. The company specializes in minimally invasive intrauterine treatments for Abnormal Uterine Bleeding (AUB), offering a comprehensive suite of products designed for safety, efficiency, and effectiveness. Solutions are provided for both normal and irregular-shaped uteri, addressing root causes with technologies like endometrial ablation and hysteroscopy systems. Support, training, and education are extended to healthcare professionals across various settings, including hospitals and private practices. The focus remains on gynecologic surgery advancements within the healthcare sector.
- Headquarters Redwood City, United States
- Employees 155
- Stage Public
- SectorsHealthcare
- Phone•••• ••••
- Website minervasurgical.com
- Social LinkedIn Facebook Instagram
- Legal Name Minerva Surgical, Inc.
- Annual Revenue$50.29 M (USD)-3.47as on Dec 31, 2022
- Net Profit-$34.11 M (USD)-58.93as on Dec 31, 2022
- EBITDA-$28.56 M (USD)-57.82as on Dec 31, 2022
- Total Equity Funding$135.1M (USD)
in 16 rounds
- InvestorsAccelmed
& 1 more
- Employee Count155
Products & Services of Minerva Surgical
Minerva Surgical offers a comprehensive portfolio of products and services, including Minerva EAS, Symphion, Genesys HTA, Resectr, and HERizon.
Endometrial ablation system using multiple tissue ablation methods.
Operative hysteroscopy system for fibroid and polyp removal.
Endometrial ablation device with continuous direct visualization feature.
Tissue resection device designed for ease and control.
Disposable hysteroscopy system for in-office diagnostic evaluation.
Funding Insights of Minerva Surgical
Minerva Surgical has successfully raised a total of $135.1M across 16 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $135.1M
- Total Rounds 16
- First Round $1.75M
(Jan 2009)
- Investors Count 2
Latest 10 of 16 funding rounds of Minerva Surgical with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2023 | Post-IPO | – | – | ||
| May 2020 | $15M | Debt – Conventional | – | – | – |
| Nov 2019 | $10M | Debt – Conventional | – | – | – |
| May 2019 | $10.23M | Series C | – | – | – |
| Jan 2019 | $9.2M | Series C | – | – | – |
| Mar 2018 | $10M | Debt – Conventional | – | – | – |
| Dec 2016 | $16.72M | Series C | – | – | – |
| Dec 2015 | $15M | Series C | – | – | – |
| Sep 2014 | $25.52M | Series C | – | – | – |
| Dec 2012 | $20M | Series B | – | – | – |
2 investors in total: 2 institutional.
Investors in Minerva Surgical
Minerva Surgical has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Accelmed and NEA.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| accelmed.com | ||||
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States |
Investor details for Minerva Surgical
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Minerva Surgical
41 people are tracked at Minerva Surgical (11 in leadership, 4 in board & advisors, 26 in team); the tracked headcount is 155.
| Name | Role | Group |
|---|---|---|
David Clapper | CEO | Leadership |
Wendy Bowman | VP, Human Resources | Leadership |
Sean Darby | Senior Director Of Research Development | Leadership |
Eugene V. Skalnyi | Chief Medical Officer | Leadership |
Arleen Felt | VP, Quality Assurance | Leadership |
Greg Simbro | VP Of Finance | Leadership |
Jarrad Soscia | Senior Regional Sales Director | Leadership |
Erik Reese | Vice President Of Sales | Leadership |
Gino Capone | Sr. Regional Sales Director | Leadership |
Jerome Bauersfeld | Regional Sales Director | Leadership |
Andrew Turman | Area Sales Director | Leadership |
Uri Geiger | Director | Board & advisors |
Daniel Cohen | Director | Board & advisors |
Ali Behbahani | Director | Board & advisors |
Catherine Coste | Director | Board & advisors |
Ryan Bonnell | Senior National Accounts Manager | Team |
Matt Pestinger | Territory Manager | Team |
Frank Wang | Sr. R&d Engineer | Team |
Robert Krulik | Senior Data Scientist | Team |
Ravon Termine | Customer Experience Manager | Team |
21 more people are available in the full profile.
Complete people profiles for Minerva Surgical
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Minerva Surgical
Minerva Surgical is a publicly listed company on the OTC with ticker symbol UTRS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date22 Oct 2021
- Listed onNASDAQ: UTRS
- Listed entityMinerva Surgical, Inc.
- Exchange sectorHealth technology
- ISINUS60343F2056
- Share price$0.00 · 2026-09-29
- Market capitalisation$887.86
- Volume (last session)426
Financials of Minerva Surgical
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2022 | $50.3M | -$34.1M | -$28.6M |
| 2021 | $52.1M | -$21.5M | -$18.1M |
Detailed financial statements for Minerva Surgical
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Minerva Surgical
4 dated milestones of Minerva Surgical across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Minerva Surgical is founded.
- Funding First funding round of $1.8M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO,.
Competitors of Minerva Surgical
Minerva Surgical has 3 listed competitors in our database, 2 of them funded. They include Gynesonics, Channel Medsystems and LUMINELLE.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| gynesonics.com | 2005 | Redwood, United States | $282.54M | 92 | A minimally invasive ablation system for uterine fibroids is developed. | |
| channelmedsystems.com | 2009 | San Francisco, United States | $47.67M | 37 | Cryothermic technology for endometrial ablation to control heavy bleeding | |
| luminelle360.com | 2016 | Raleigh, United States | Hysteroscopy system is developed for minimally invasive endometrial procedures. |
Detailed competitors of Minerva Surgical
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Minerva Surgical
The website of Minerva Surgical (minervasurgical.com) receives about 3.7K visits a month.
- Monthly visits3.7K
▲ 7.5% vs previous month
Top companies in Women's Health & Fertility
3 companies that operate in the same segment as Minerva Surgical (Women's Health & Fertility) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of cell-free DNA testing for oncology, women’s health, and organ health | 2004 | Redwood City, California, United States | USD 152.1 M | USD 2.31 B | 4,430 | |
Therapeutics for women's healthcare are developed and offered. | 1997 | Princeton, New Jersey, United States | USD 123.06 M | USD 19.59 M | ||
Provider of cell-free cancer liquid biopsy test | 2015 | San Francisco, California, United States | USD 388.62 M | 861 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Minerva Surgical
Complete news archive for Minerva Surgical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Minerva Surgical
Minerva Surgical was founded in 2008 and raised its 1st funding round 1 year after it was founded.
Minerva Surgical is headquartered in Redwood City, United States. It is registered at Redwood City, California, United States.
David Clapper is the CEO of Minerva Surgical, as recorded in our data.
Minerva Surgical is a funded company, having raised a total of $135.1M across 16 funding rounds to date. The company's 1st funding round was a Series B of $20M, raised on Jan 2009.
Minerva Surgical has 155 employees.
Annual revenue of Minerva Surgical is $50.29M as on Dec 31, 2022.
Minerva Surgical, Inc. is dedicated to advancing womens uterine health through innovative medical devices. The company specializes in minimally invasive intrauterine treatments for Abnormal Uterine Bleeding (AUB), offering a comprehensive suite of products designed for safety, efficiency, and effectiveness. Solutions are provided for both normal and irregular-shaped uteri, addressing root causes with technologies like endometrial ablation and hysteroscopy systems. Support, training, and education are extended to healthcare professionals across various settings, including hospitals and private practices. The focus remains on gynecologic surgery advancements within the healthcare sector.
Minerva Surgical's top competitors include Gynesonics, Channel Medsystems and LUMINELLE.
Minerva Surgical offers Minerva EAS, Symphion, Genesys HTA, Resectr, and HERizon.
Yes, Minerva Surgical is publicly traded on OTC under the ticker symbol UTRS.
Minerva Surgical has 2 investors. Key investors include Accelmed, and NEA.
Minerva Surgical operates through Minerva Surgical, Inc..